Eletriptan review.

Abstract

Eletriptan is a selective, high affinity serotonin 5-HT(1B/1D)-receptor agonist which is rapidly absorbed and has a long half-life in plasma. Eletriptan has been shown to be effective and well tolerated in randomised, double-blind, placebo-controlled acute migraine trials and long-term open-label trials. Eletriptan maintains a consistency of response across three attacks and patients continue to respond to eletriptan for at least up to 1 year. Eletriptan has been compared with sumatriptan, zolmitriptan, naratriptan and ergotamine/caffeine in placebo-controlled, randomised, head-to-head trials, and has shown better efficacy with similar adverse events. In a large triptan meta-analysis, including 53 trials and > 24,000 patients, eletriptan 80 mg showed better efficacy, similar consistency but lower tolerability compared with sumatriptan 100 mg. Eletriptan has also shown efficacy in difficult-to-treat patients who were dissatisfied with their previous treatment with sumatriptan, rizatriptan, nonsteroidal anti-inflammatory drugs or Excedrin.

• Authors: Markus Färkkilä, Mikko Kallela
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 6 Issue 4 Pg. 625-30 (Apr 2005) ISSN: 1744-7666 [Electronic] England
• PMID: 15934888 (Publication Type: Journal Article, Review)

Chemical References

• Pyrrolidines
• Serotonin Receptor Agonists
• Tryptamines
• eletriptan

Topics

• Clinical Trials as Topic (statistics & numerical data)
• Dose-Response Relationship, Drug
• Humans
• Migraine Disorders (drug therapy, metabolism)
• Pyrrolidines (metabolism, therapeutic use)
• Serotonin Receptor Agonists (metabolism, therapeutic use)
• Tryptamines (metabolism, therapeutic use)